Gemeinschaftspraxis Drs. Grosskopf
- Address
- Ahornstr. 2a, 94574 Wallerfing, Germany
Respiratory Tract Diseases
The site is conducting research on the immune response to a novel respiratory syncytial virus vaccine in adults aged 60 and older, aiming to improve protection against seasonal infections.
- Evaluation of humoral immunity after revaccination
- Assessment of vaccine safety in elderly participants
- Timing of booster doses across different RSV seasons
Gemeinschaftspraxis Drs. Grosskopf contributes valuable data to the field of respiratory viral prevention.
Skin and Connective Tissue Diseases
A comparative study is testing a new topical formulation containing clotrimazole and betamethasone dipropionate for the treatment of moderately to severely inflamed candidiasis of the skin, with the goal of enhancing therapeutic outcomes.
- Comparison of combination ointment versus standard therapy
- Safety profile of anti‑fungal and anti‑inflammatory agents together
- Patient‑reported symptom relief and healing rates
The practice’s dermatology focus supports advances in managing fungal skin infections.
Virus Diseases
Research at the center also explores broader viral health by monitoring immune responses to revaccination with an RSVPreF3 OA vaccine, seeking to strengthen defenses against common respiratory viruses in older adults.
- Immunogenicity across multiple vaccination seasons
- Cross‑reactivity with other respiratory pathogens
- Long‑term safety monitoring post‑vaccination
These efforts align with the site’s commitment to combating viral diseases within the community.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GlaxoSmithKline Biologicals2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis Drs. Grosskopf
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin | Dermapharm AG | Phase III | Recruiting | Mar 2022 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E | 2 | Unknown | 2021-02-22 | 2024-08-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.